Press Release No. 035/KFCP-DIR/PR/IX/20
Jakarta, 12 September 2020, PT Kalbe Farma Tbk (Kalbe) through its subsidiary PT Enseval Medika Prima (EMP) in collaboration with bioMerieux and the Association of Indonesian Clinical Pathology and Laboratory Medicine Specialists (Patklin) conducted health education on COVID-19 detection with syndromic testing that is an examination using the Rapid Multiplex Polymerase Chain Reaction (PCR) which can detect genetic material from several target pathogenic microorganisms at once. Sources of this health education events are Prof. Dr. H. Abdul Kadir, PhD, Sp.THT-KL(K), MARS - Interim Director General of Health Services of teh Ministry of Health of the Republic of Indonesia, Dr. Julien TEXTORIS, MD, Ph.D. – VP Global Medical Affair of bioMerieux, Prof. DR. Dr. Aryati, MS, Sp.PK(K) – RSUD Dr. Soetomo Surabaya, DR. Dr. Tonny Loho, DMM., Sp.PK(K) – RS. Medistra Jakarta, Prof. DR. Dr. Ida Parwati, Sp.PK(K), PhD – RS Dr. Hasan Sadikin Bandung, and Adj. Prof. Hananiel Prakasya Widjaya – CEO of National Hospital Surabaya.
“Currently we have 322 COVID-19 Examination Laboratories that are standardized according to WHO standards, spread across Indonesia that faces various challenges, among others; human resources, limited laboratories, specialized lab technicians, laboratory design infrastructure, RT PCR machines, availability of reagents and consumables as well as reagent validity, “said Prof. Dr. H. Abdul Kadir, Ph.D., Sp.THT-KL (K), MARS - Int. Director-General of Health Services, Ministry of Health. “Toward the future, we will sustain and increase the quality of the laboratories including their biosafety and biosecurity, strengthen the laboratories network, improve the national laboratories' data management, and strengthen the Covid-19 research and development collaboration,” he continued.
“EMP as a subsidiary of Kalbe which operates in the field of medical and diagnostic equipment is committed to supporting the government in preventing, anticipating, diagnosing and handling the spread of COVID-19, one of which is by providing molecular laboratory examination tools to detect and diagnose viruses and examinations using the ELISA method. to detect antibodies produced by the body,” said Sudirman, Business Unit Manager of PT Enseval Medika Prima. “The molecular examination can be conducted for several pathogens at the same time (syndromic testing) with a length of examination to result taking only 45 minutes,” he continued.
Sudirman explained that in the examination technology that is referred to as Rapid Multiplex PCR, EMP is collaborating with bioMerieux Francis that produces and developed the in-Vitro Diagnostic Syndromic testing solution called Bio-Fire Film Array (system, reagents, software, and after-sales service) for the use of government and private hospitals or laboratories to diagnose contagious diseases such as Covid-19.
Sudirman continued that aside from the diagnostic, disease medication management has become just as important since most of the Covid-19 fatalities would have secondary accompanying illnesses or co-infection (additional infection). Co-infection can worsen the patient's condition and can cause death if not handled quickly and properly. The more commonly happened co-infection are bacterial and viral infections that would cause the patient's condition to worsen rapidly. According to him, to manage the bacterial infection, a rational and proper antibiotic dosage is very important. Therefore a culture examination is required to investigate the pathogen of the bacteria that are infecting, including the correct anti-microbial that can handle the infection.
PT Enseval Medika Prima (EMP) at a glance
PT Enseval Medika Prima, a subsidiary of Kalbe Group that runs in the field of healthcare equipment marketing, is implementing the strategy of dividing marketing teams based on the target market focus. As an agent of a number of healthcare equipment types from a good number of principals, PT Enseval Medika Prima is confident that it is able to provide a number of solutions to answer market demands.
EMP is focused on the market, in providing numerous solutions to fulfill the market needs. Thus the experience of our customers in using our products become an important baseline for us, in order for us to provide products that are even more innovative for our customers.
BioMerieux at a glance
bioMerieux was established by Marcell Merieux who was an assistant of Louis Pasteur whose focus was on microbiology and is very influential to the development of the company. As an In-Vitro Diagnostic (IVD) company that focuses on microbiology examination, bioMerieux has formed into a company with the most complete microbiology platform starting from the manual to the automatic. Alongside the development of knowledge, bioMerieux has started to develop other platforms, i.e. immunoassay examination that is used for the detection of both contagious and non-contagious diseases and other examinations relating to a patient's health. Aside from the two abovementioned platforms, bioMerieux also develops molecular examination whether it is a target-specific or syndromic testing.
Kalbe at a glance
PT Kalbe Farma Tbk (“Kalbe”) was established in 1966 and is one of the largest listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); health product division that handles over-the-counter medication (Promag, Mixagrip, Komix, Woods, Fatigon, etc.); multivitamins (Fatigon, H2, XonCe, Hevit-C, JossC1000, etc.); as well as supplement and ready-to-consume drinks (Hydro Coco, Extra Joss); nutrition division (ChilKid, Prenagen, Diabetasol, Zee, etc,); and distribution division. Kalbe now has more than 40 subsidiaries, 14 production facilities with international standards, and employs approximately 17,000 employees, spread in more than 76 branches throughout Indonesia. Since 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).